A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Mar 2023 Status changed from completed to discontinued.
- 30 Sep 2022 Status changed from active, no longer recruiting to completed.
- 19 May 2021 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.